Distribution of actin isoforms in sarcomas: an immunohistochemical study. 1990

P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
Institute of Pathology, University Hospital Utrecht, The Netherlands.

The actin immunophenotype of eight benign mesenchymal tumors, 14 nonsarcomatoid tumors, and 46 sarcomatoid tumors was studied, using monoclonal antibodies (MoAb) specific for alpha-smooth muscle actin (clone 1A4), alpha- and gamma-smooth muscle actin (designated CGA7), and muscle actin (designated HHF35) on frozen sections. Tumor cells of nonsarcomatoid tissues were not reactive, but all leiomyomas and five of the seven leiomyosarcomas reacted with the three MoAbs. One leiomyosarcoma was immunoreactive for the MoAb 1A4 only. One of the six malignant schwannomas showed staining for muscle actin (HHF35). The 22 malignant fibrous histocytomas (MFH) expressed these actin isoforms in various degrees. One case immunoreacted with all three MoAbs, three reacted with 1A4 only, seven reacted with CGA7 and HHF35, and two reacted with HHF35 only. Nine MFHs were not immunoreactive for any of the MoAbs specific for (smooth) muscle and actin. In addition, the expression of desmin and collagen type IV was investigated for the group of leiomyosarcomas and MFHs. Desmin was found in five leiomyosarcomas and in two MFHs. Collagen type IV was seen in all leiomyosarcomas, and was seen weakly in a few small areas in four MFHs. When we take into account the expression of all markers tested [( smooth] muscle actin, desmin, and collagen type IV), then six of the 22 MFHs were unreactive for all these markers. Five of these six tumors were located intramuscularly, whereas only half of the total number of MFH cases had an intramuscular location. The fact that 15 of 22 MFHs displayed one or more markers linked with (smooth) muscle differentiation suggests that some of the MFHs may be classified as poorly differentiated leiomyosarcomas, and that MFH is not a unique entity.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D003893 Desmin An intermediate filament protein found predominantly in smooth, skeletal, and cardiac muscle cells. Localized at the Z line. MW 50,000 to 55,000 is species dependent. Skeletin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012509 Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas
D012983 Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. Neoplasm, Soft Tissue,Neoplasms, Soft Tissue,Soft Tissue Neoplasm
D018219 Histiocytoma, Benign Fibrous A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747) Dermatofibroma,Hemangioma, Sclerosing,Histiocytoma, Cutaneous,Histiocytoma, Fibrous,Angioma, Sclerosing,Benign Fibrous Histiocytoma,Angiomas, Sclerosing,Benign Fibrous Histiocytomas,Cutaneous Histiocytoma,Cutaneous Histiocytomas,Dermatofibromas,Fibrous Histiocytoma,Fibrous Histiocytoma, Benign,Fibrous Histiocytomas,Fibrous Histiocytomas, Benign,Hemangiomas, Sclerosing,Histiocytomas, Benign Fibrous,Histiocytomas, Cutaneous,Histiocytomas, Fibrous,Sclerosing Angioma,Sclerosing Angiomas,Sclerosing Hemangioma,Sclerosing Hemangiomas

Related Publications

P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
May 1995, Molecular biology of the cell,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
January 2007, Pathology, research and practice,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
December 2022, Biomedicines,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
January 2004, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
January 1989, Annales de pathologie,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
February 1993, Current opinion in cell biology,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
April 2005, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
May 2011, Placenta,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
December 2021, Annals of diagnostic pathology,
P J Roholl, and H R Elbers, and I Prinsen, and J A Claessens, and J A van Unnik
December 2004, Endocrine regulations,
Copied contents to your clipboard!